Skip to main content

Waters Nearly Doubles Q3 Profit, Revenues Increase 10 Percent

NEW YORK (GenomeWeb News) - Waters today reported a 10 percent increase in revenues and nearly doubled net income for the third quarter of 2005.
The mass spectrometry, chromatography and software company posted net income of $50.4 million for the quarter ended Sept. 30 –- a 96-percent increase over $25 million last year.
Total revenue rose to $300 million from $273 million in the third quarter of 2005.
Company chairman, president, and CEO Douglas Berthiaume credited the revenue increase to improved pharmaceutical spending in the US, expanding sales in Asia, efficient operations, and “overall positive acceptance and uptake” of the company's Acquity UPLC system. 
R&D spending rose to $19.1 million from $17 million in the prior-year period.
As of Sept. 30, Waters had $511.6 million in cash and cash equivalents.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.